Moderate sodium restriction is an important part of patient management, with a daily sodium limit of 80 to 120 mmol/L, equivalent to 4.6 to 6.9 g of salt per day. 2. There is insufficient evidence to recommend bed rest as part of the treatment of ascites, and fluid restriction is not recommended for those with normal blood sodium concentrations. Patients with first presentation of grade 2 or higher ascites should receive an aldosterone antagonist, such as spironolactone alone, at an initial dose of 100 mg/d, gradually increasing to a maximum dose of 400 mg/d if there is no response. patients who do not respond to an aldosterone antagonist (<2 kg body mass loss per week) or who develop hyperkalemia, gradually add furosemide, starting at 40 mg/d and increasing by 40 mg/d each time to a maximum dose of 160 mg/d. The maximum dose is 160 mg/d. 4. During diuretic therapy, the high limit of daily body mass reduction is 0.5 kg in the absence of peripheral edema and 1 kg in the presence of peripheral edema. diuretics are discontinued when ascites subsides. 5. Discontinue all diuretics in the presence of severe hyponatremia (<120 mmol/L), progressive renal failure, worsening hepatic encephalopathy, or severe muscle spasms. In severe hypokalemia (<3 mmol/L), discontinue furosemide and in severe hyperkalemia (>6 mmol/L), discontinue aldosterone antagonists. 6. Massive laparotomy fluid release (LVP) is the preferred treatment option for grade 3 ascites and should be done in one visit. To prevent circulatory dysfunction after LVP, LVP should be followed by an intravenous drip of 8 g of albumin for every 1 L of ascites released. Plasma bulking agents other than albumin are not recommended. After massive release of ascites, patients must be treated with minimal doses of diuretics to prevent relapse. 7. Non-steroidal anti-inflammatory drugs are contraindicated in patients with cirrhotic ascites, and no drugs that lower arterial blood pressure or renal blood flow such as ACEI-like, ARB-like and α-adrenergic receptor blockers, and no aminoglycoside antibiotics are used. (1) In patients with massive ascites, bed rest can help improve hepatic and renal blood flow, and bed rest should be recommended for such patients. (2) The treatment of ascites emphasizes individualized treatment plan, and the dose of drugs should be different from person to person. for grade 2 or higher ascites, we have learned that initial treatment with aldosterone antagonists combined with potassium-depleting diuretics is more effective, which can reduce the amount of single drugs, shorten the course of treatment, and avoid the adverse effects of drugs. (3) Although LAV is the first treatment option for grade 3 ascites, we believe that for non-refractory ascites, the first treatment should be a combination of diuretic-based therapy, as massive release of ascites will cause more peritoneal leakage, resulting in insufficient hemolysis and excessive activation of the renin-angiotensin-aldosterone system, which will further increase sodium retention. This is exacerbated by excessive activation of the renin-angiotensin-aldosterone system. Secondly, when LAV is performed, albumin supplementation should be started when 1 L of ascites is released, not after LAV is finished, otherwise, HRS is easily induced. (4) Although the European and American guidelines for the treatment of cirrhotic ascites do not mention ascitic fluid ultrafiltration concentration and transfusion, according to our experience, the treatment of grade 3 ascites with ascitic fluid ultrafiltration concentration and transfusion is more effective than LAV, and further application and conclusion are recommended.